Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Tang Capital Management LLC

Tang Capital Management LLC grew its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 225.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,900,000 shares of the company's stock after purchasing an additional 4,087,005 shares during the period. Tang Capital Management LLC owned approximately 4.29% of Compass Therapeutics worth $8,555,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CMPX. Tower Research Capital LLC TRC increased its position in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Financial Markets acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $27,000. Mariner LLC acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $30,000. Finally, ProShare Advisors LLC increased its position in shares of Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares during the period. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX traded down $0.04 on Wednesday, reaching $2.06. The company's stock had a trading volume of 387,340 shares, compared to its average volume of 918,392. The stock's 50-day moving average is $1.92 and its two-hundred day moving average is $2.11. Compass Therapeutics, Inc. has a 52-week low of $0.77 and a 52-week high of $4.08. The stock has a market capitalization of $284.86 million, a P/E ratio of -5.57 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). Equities analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jonathan Anderman bought 20,000 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The shares were purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Company insiders own 29.80% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on CMPX. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Piper Sandler assumed coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Finally, D. Boral Capital restated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $13.13.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.